Ziftomenib is under clinical development by Kura Oncology and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ziftomenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ziftomenib overview
Ziftomenib (KO-539) is under development for the treatment of MLL- rearranged leukemias including NPM1 mutant or DNMT3A mutant refractory/relapsed acute myelocytic leukemia and adult, pediatric acute lymphocytic leukemia (ALL, acute lymphoblastic leukemia) and type 2 diabetes. The drug candidate is administered orally as a capsule. It targets menin-MLL protein interaction.
Kura Oncology overview
Kura Oncology is a biopharmaceutical company that primarily focuses on the discovery and development of precision medicines for cancer treatment. Its main activities include the design of novel therapies that selectively target cancer cells, aiming to increase clinical benefits and address areas with high unmet needs. The company’s major products are its pipeline of precision medicines, including Ziftomenib, Tipifarnib, and KO-2806. Kura Oncology‘s products are primarily used in the healthcare industry, specifically in the treatment of blood cancers and solid tumors. The company’s target market appears to be patients with cancer, particularly those with blood cancers and solid tumors. Kura Oncology is headquartered in San Diego, California, the US.
For a complete picture of Ziftomenib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
